- Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth
Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth
Oncotarget (2017-12-22)
Zhenghu Chen, Yanling Zhao, Yang Yu, Jonathan C Pang, Sarah E Woodfield, Ling Tao, Shan Guan, Huiyuan Zhang, Shayahati Bieerkehazhi, Yan Shi, Roma Patel, Sanjeev A Vasudevan, Joanna S Yi, Jodi A Muscal, Guo-Tong Xu, Jianhua Yang
PMID29262623
ABSTRACT
Neuroblastoma (NB), the most common extracranial pediatric solid tumor, continues to cause significant cancer-related morbidity and mortality in children. Dysregulation of oncogenic receptor tyrosine kinases (RTKs) has been shown to contribute to tumorigenesis in various human cancers and targeting these RTKs has had therapeutic benefit. RET is an RTK which is commonly expressed in NB, and high expression of RET correlates with poor outcomes in patients with NB. Herein we report that RET is required for NB cell proliferation and that the small molecule inhibitor regorafenib (BAY 73-4506) blocks glial cell derived neurotrophic factor (GDNF)-induced RET signaling in NB cells and inhibits NB growth both
MATERIALS
Product Number
Brand
Product Description
Sigma-Aldrich
Phosphatase Inhibitor Cocktail 2, aqueous solution (dark coloration may develop upon storage, which does not affect the activity)
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, purified immunoglobulin, buffered aqueous solution